跳至主要内容
临床试验/NL-OMON43867
NL-OMON43867已完成不适用

Beneficial effects of the amino-acid food supplement L-Citrulline in Participants with Peripheral artery disease - CIPER

niversiteit Maastricht0 个研究点目标入组 16 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * 40 years or older males and postmenopausal women;
  • * male participants must agree to using an adequate form of contraception during the study period;
  • * 6-month history of stable intermittent claudication (IC) due to PAD;
  • * PAD secondary to atherosclerosis with significant claudication (Fontaine class II defined as IC, or Fontaine class III defined as pain at rest);
  • * IC characterised by pain, ache, cramp, numbness or severe fatigue involving muscles of one or both lower extremities, reproducibly provoked by walking and relieved by rest;
  • * ankle-brachial index (ABI) at rest of <0.9 and at least 25% decrease in ABI within 1 min during exercise recovery;
  • * capacity to walk more than 2 min/15 meters but no more than 12 min on a treadmill using the Skinner-Gardner protocol;
  • * walking limited by claudication, not coexisting conditions; and
  • * difference between two consecutive baseline exercise treadmill tests of <25% during the 3-weeks run-in period; and
  • * no change in medications or physical activity within 3 months prior to enrolment.

排除标准

  • * Women of child-bearing potential;
  • * Current enrolment in another clinical trial and/or ingestion of another investigational product within the past 30 days before enrolment;
  • * PAD of non-atherosclerotic nature;
  • * Fontaine class IV i.e. ulcer or gangrene;
  • * leg amputation above the ankle;
  • * peripheral vascular surgery, sympathectomy, peripheral angioplasty or stent insertion within the previous 3 months;
  • * myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery within the previous 3 months;
  • * uncontrolled hypertension (resting SBP >190 or DBP >115 mmHg);
  • * hypotension (SBP <90mmHg);
  • * type I diabetes, proliferative retinopathy;
  • * history of disease state or surgery that affects gastrointestinal absorption;
  • * significant renal disease (serum creatinine >3.0 mg/dl);
  • * liver disease (transaminase > 3x upper limit of normal, bilirubin >1.5 times upper limits of normal);
  • * history of treatment for any malignancy within the past 5 years, or evidence of active malignancy other than squamous cells or basal cell carcinoma of the skin;
  • * serious infection or hypotension associated with sepsis in the last month;
  • * cerebrovascular infarct in the last 3 months;
  • * autoimmune disorders (e.g. systemic lupus erythematosis, ulcerative colitis);
  • * any other acute or chronic medical condition that in the opinion of the investigators increases the likelihood that the participant would be unable to complete the study;
  • * unwillingness to discontinue arginine- or L-citrulline-containing products, pentoxifylline, L-carnitine, or prostacyclin for at least 1 month prior to and during the study; and
  • * conditions other than PAD that limit walking distance.

研究者

相似试验